Abstract
PVI 5FU gives increased response rates and reduced toxicity when compared to bolus 5FU (J Clin Oncol 1989, 425–432). PVI 5FU administration was reported to give highly variable (>1000-fold) plasma 5FU concentrations at steady state (FU Css) which correlated with toxicity (Ann Oncol 1996, 47–53); but only 19 patients were studied. Therefore, we performed a study of PVI 5FU in 61 patients with advanced colorectal cancer to assess the variability (inter- and intra-subject) in 5FU Css associated with PVI 5FU (300 mg m−2 day−1) and to attempt to correlate pharmacodynamic end-points (anti-tumour activity, toxicity) with 5FU Css as a prelude to ‘exposure-guided’ 5FU administration. All 5FU sampling was performed between 10 am and noon. PVI 5FU administration continued to 26 weeks in patients with disease improvement or stabilization. The response rate was 26% (33% stable disease) and median survival was 11 months. Hand–foot syndrome was the most common dose limiting toxicity. Variability in 5FU300Css was considerably less than previously reported; 94 ± 25 ng ml−1(CV = 27%). No relationships were demonstrated between subject mean 5FU300Css and PD end-points such as response, mucositis, diarrhoea and hand–foot syndrome. The lack of correlation suggests that measurement of 5FU concentrations should not be used to individualize dosing in patients receiving PVI 5FU for advanced colorectal cancer. © 2001 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
D’Argenio DZ and Schumitsky A ADAPT II User’s Guide, Biomedical Simulations Resource, University of Southern California: Los Angeles, CA
Etienne MC, Milano G, Lagrange JL, Bajard F, Francois E, Thyss A, Schneider M, Renee N and Fety R (1993) Marked fluctuations in drug plasma concentrations caused by use of portable pumps for fluorouracil continuous infusion (letter). J Natl Cancer Inst 85: 1005–7
Etienne MC, Lagrange JL, Dassonville O, Fleming R, Thyss A, Renee N, Schneider M, Demard F and Milano G (1994) Population study of dihydropyrimidine dehydrogenase in cancer patients. J Clin Oncol 12: 2239–2242
Fety R, Rolland F, Campion L, Perrocheau G, Merlin JL, Barberi-Heyob M, Conroy T, Hardouin A, Riviere A and Milano G (1997) A multicentric randomised trial of 5-fluorouracil (FU) dose adaptation (DA) based on pharmcokinetics (PK). Clinical and Economic Impacts. Proc Am Soc Clin Oncol 16: 225a
Findlay MPN, Raynaud F, Cunningham D, Iveson A, Collins DJ and Leach MO (1996) Measurement of plasma 5FU by HPLC with comparison of results to tissue drug levels observed using in vivo MRS in patients on a PVI with or without interferon a. Annal Oncol 7: 47–53
Fleming RA, Milano G, Thyss A, Etienne MC, Renee N, Schneider M and Demard F (1992) Correlation between dihydropyrimidine dehydrogenase-activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients. Cancer Res 52: 2899–2902
Gamelin E, Bosidron-Celle M, Delva R, Regimbeau C, Cailleux PE, Alleaume C, Maillet ML, Goudier MJ, Sire M, Person-Joly MC, Maigre M, Maillart P, Fety R, Burtin P, Lortholary A, Dumesnil Y, Picon L, Geslin J, Gesta P, Danquechin-Dorval E, Larra F and Robert J (1998) Long-term weekly treatment of colorectal metastatic cancer with fluorouracil and leucovorin: results of a multicentric prospective trial of fluorouracil dosage optimisation by pharmacokinetic monitoring in 152 patients. J Clin Oncol 16: 1470–1478
Harris BE, Carpenter JT and Diasio RB (1991) Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency. A potentially more common pharmacogenetic syndrome. Cancer 68: 499–501
Harris BE, Song R, Soong S and Diasio RB (1990) Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res 50: 197–201
Lokich JL, Ahlgren JD, Gullo JJ, Philips JA and Fryer JG (1988) A prospective randomised comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a mid-Atlantic oncology program study. J Clin Oncol 7: 425–432
Lu Z, Zhang R and Diasio RB (1993) Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients and clinical implication in 5-fluorouracil chemotherapy. Cancer Res 53: 5433–5438
Meta-analysis Group in Cancer (1998) Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 16: 301–308
Santini J, Milano G, Thyss A, Renee N, Viens P, Ayela P, Schneider M and Demard F (1989) 5FU therapeutic monitoring with dose adjustment leads to an improved therapeutic index in head and neck cancer. Br J Cancer 59: 287–90
Seymour MT, Patel N, Johnston A, Joel SP and Slevin ML (1994) Lack of effect of interferon 2α upon fluorouracil pharmacokinetics. Br J Cancer 70: 724–728
McMurrough McLeod (1996) Analysis of the DPD polymorphism in a British population. Br J Clin Pharmacol 41: 425–427
Vokes BE, Mick R, Kios MS, Dolan ME, Malone D, Athanasiadis J, Daraf DJ, Kozloff M, Weichselbaum RR and Ratain MJ (1996) Pharmacodynamics of fluorouracil-based induction chemotherapy in advanced head and neck cancer. J Cancer Oncol 14: 1663–71
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Jodrell, D., Stewart, M., Aird, R. et al. 5-fluorouracil steady state pharmacokinetics and outcome in patients receiving protracted venous infusion for advanced colorectal cancer. Br J Cancer 84, 600–603 (2001). https://doi.org/10.1054/bjoc.2000.1664
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2000.1664
Keywords
This article is cited by
-
Is monitoring of plasma 5-fluorouracil levels in metastatic / advanced colorectal cancer clinically effective? A systematic review
BMC Cancer (2016)
-
Gender-specific elimination of continuous-infusional 5-fluorouracil in patients with gastrointestinal malignancies: results from a prospective population pharmacokinetic study
Cancer Chemotherapy and Pharmacology (2013)
-
Failure to complete adjuvant chemotherapy is associated with adverse survival in stage III colon cancer patients
British Journal of Cancer (2007)
-
A preclinical evaluation of pemetrexed and irinotecan combination as second-line chemotherapy in pancreatic cancer
British Journal of Cancer (2007)
-
Analysis of the time course and prognostic factors determining toxicity due to infused fluorouracil
British Journal of Cancer (2003)